Immunome, Inc. (NASDAQ:IMNM) Given Consensus Recommendation of “Moderate Buy” by Brokerages

by · The Cerbat Gem

Shares of Immunome, Inc. (NASDAQ:IMNM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $30.0909.

A number of research analysts recently issued reports on the stock. Lake Street Capital boosted their target price on shares of Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a report on Wednesday, October 8th. The Goldman Sachs Group assumed coverage on shares of Immunome in a research report on Monday, September 22nd. They set a “buy” rating and a $26.00 price objective on the stock. Wall Street Zen raised Immunome from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, Evercore ISI increased their price target on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th.

Check Out Our Latest Stock Report on IMNM

Insider Activity at Immunome

In other Immunome news, insider Philip Tsai purchased 10,000 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was acquired at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the purchase, the insider owned 43,300 shares of the company’s stock, valued at $887,217. This trade represents a 30.03% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Clay B. Siegall acquired 4,729 shares of the company’s stock in a transaction on Tuesday, December 30th. The stock was acquired at an average cost of $21.15 per share, for a total transaction of $100,018.35. Following the completion of the purchase, the chief executive officer directly owned 665,254 shares of the company’s stock, valued at approximately $14,070,122.10. This represents a 0.72% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 68,518 shares of company stock valued at $1,453,958. 7.69% of the stock is owned by company insiders.

Institutional Trading of Immunome

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of Immunome by 8.1% in the third quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company’s stock valued at $57,304,000 after purchasing an additional 368,674 shares in the last quarter. Geode Capital Management LLC lifted its stake in Immunome by 6.7% during the 2nd quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock valued at $17,305,000 after acquiring an additional 117,523 shares in the last quarter. Woodline Partners LP lifted its stake in Immunome by 69.0% during the 1st quarter. Woodline Partners LP now owns 1,657,729 shares of the company’s stock valued at $11,157,000 after acquiring an additional 676,804 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Immunome by 222.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after acquiring an additional 762,147 shares during the last quarter. Finally, Polar Capital Holdings Plc grew its stake in shares of Immunome by 5.9% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,058,776 shares of the company’s stock worth $12,398,000 after acquiring an additional 58,776 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $21.07 on Monday. Immunome has a 1 year low of $5.15 and a 1 year high of $25.30. The business’s 50-day moving average is $19.27 and its 200-day moving average is $14.01. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -7.14 and a beta of 2.22.

Immunome (NASDAQ:IMNM – Get Free Report) last issued its earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. Analysts anticipate that Immunome will post -2.21 EPS for the current year.

About Immunome

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

Featured Stories